Correction to: Nature Communications https://doi.org/10.1038/s41467-023-35961-y, published online 27 February 2023
The original Article contained errors in the legend of Figure 3 that incorrectly read “Comparator EGFR-TKI duration of treatment by candidate resistance mechanisms. Swimmer plot indicating duration of treatment with comparator EGFR-TKI (months) by resistance mechanisms (n = 145).”. This has been corrected and the legend now reads: “Osimertinib duration of treatment by candidate resistance mechanisms. Swimmer plot indicating duration of treatment with osimertinib (months) by resistance mechanisms (n = 109 total, n = 38 with detected resistance mutation).”
Two statements in the Discussion section contained errors and have also been amended.
In the third paragraph, the original sentence “The frequency of MET amplification (16%) was similar to that observed in patients treated with second-line osimertinib in the Phase III AURA3 study (19%)” should have read “The frequency of MET amplification (16%) was similar to that observed in patients treated with second-line osimertinib in the Phase III AURA3 study (18%)”.
In the fourth paragraph, the original sentence “An analysis of second-line osimertinib in the Phase I AURA13 (n=6) and Phase III AURA314,15 studies identified 14% of patients acquired EGFR C797S” should have read “An analysis of second-line osimertinib in the Phase III AURA314,15 study identified 14% of patients acquired EGFR C797S”.
In addition, inadvertently, data from a patient with an acquired BRAF D594N mutation (already included in Figure 2B) were not displayed in Supplementary Figure 1.
The figure and its legend have been updated accordingly in the Supplementary Information file. The original sentence in the Figure legend “Swimmer plot indicating duration of treatment with comparator EGFR-TKI (months) by resistance mechanisms (n=145 total)” now reads “Swimmer plot indicating duration of treatment with comparator EGFR-TKI (months) by resistance mechanisms (n=145 total, n = 71 with detected resistance mutation)”.
These changes do not affect the scientific conclusions of this work. Errors have been corrected in the PDF and HTML versions of the Article. The HTML has been updated to include a corrected version of the Supplementary Information.
Author information
Authors and Affiliations
Corresponding author
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Chmielecki, J., Gray, J.E., Cheng, Y. et al. Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nat Commun 14, 3179 (2023). https://doi.org/10.1038/s41467-023-38999-0
Published:
DOI: https://doi.org/10.1038/s41467-023-38999-0
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
